- $632.91m
- $797.67m
- $216.19m
- 69
- 21
- 43
- 41
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 27.47 | ||
| PEG Ratio (f) | 0.38 | ||
| EPS Growth (f) | 268.7% | ||
| Dividend Yield (f) | 0.55% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.08 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 14.72 | ||
| Price to Sales | 2.66 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -90.03% | ||
| Return on Equity | -89.38% | ||
| Operating Margin | -106.51% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 117.69 | 133.94 | 184.34 | 219.08 | 216.19 | 240.52 | 251.93 | 15.95% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -90.03 | +80.5 | -46.09 | -50.53 | n/a | n/a | +268.7 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries. Its segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. It also provides testing and laboratory services, mainly to the dental and pharmaceutical industries. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services quality control products. It has manufacturing operations in the United States and Europe.
Directors
- John Sullivan CHM (68)
- Gary Owens PRE (53)
- John Sakys CFO (52)
- Brian Archbold SVP (46)
- Greg DiNoia SVP (56)
- Shannon Hall DRC (52)
- Jennifer Alltoft IND (52)
- Evan Guillemin IND (55)
- David Kelly IND (79)
- Shiraz Ladiwala IND
- John Schmieder IND (52)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 26th, 1982
- Public Since
- February 29th, 1984
- No. of Shareholders
- 60
- No. of Employees
- 736
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 5,433,607
- Address
- 12100 W 6th Ave, LAKEWOOD, 80228-1252
- Web
- https://mesalabs.com
- Phone
- +1 3039878000
- Auditors
- RSM US LLP
Upcoming Events for MLAB
Q4 2025 Mesa Laboratories Inc Earnings Release
Q1 2026 Mesa Laboratories Inc Earnings Release
Mesa Laboratories Inc Annual Shareholders Meeting
Similar to MLAB
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the Mesa Laboratories share price?
As of Today at 22:01 UTC, shares in Mesa Laboratories are trading at $116.48. This share price information is delayed by 15 minutes.
How has the Mesa Laboratories share price performed this year?
Shares in Mesa Laboratories last closed at $116.48 and the price had moved by +14.42% over the past 365 days. In terms of relative price strength the Mesa Laboratories share price has outperformed the S&P500 Index by +5.61% over the past year.
What are the analyst and broker recommendations for Mesa Laboratories?
The overall consensus recommendation for Mesa Laboratories is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Mesa Laboratories dividend yield?
The Mesa Laboratories dividend yield is 0.55% based on the trailing twelve month period.
Does Mesa Laboratories pay a dividend?
Last year, Mesa Laboratories paid a total dividend of $0.64, and it currently has a trailing dividend yield of 0.55%.Looking ahead, shares in Mesa Laboratories are due to go ex-dividend on 2025-05-30 and the next dividend pay date is 2025-06-16.
When does Mesa Laboratories next pay dividends?
Mesa Laboratories are due to go ex-dividend on 2025-05-30 and the next dividend pay date is 2025-06-16. The historic dividend yield on Mesa Laboratories shares is currently 0.55%.
How do I buy Mesa Laboratories shares?
To buy shares in Mesa Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Mesa Laboratories?
As of the previous close price of $116.48, shares in Mesa Laboratories had a market capitalisation of $632.91m.
Where are Mesa Laboratories shares listed?
Here are the trading details for Mesa Laboratories:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: MLAB
What kind of share is Mesa Laboratories?
Based on an overall assessment of its quality, value and momentum Mesa Laboratories is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Mesa Laboratories share price forecast for 2025?
The analyst consensus target price for shares in Mesa Laboratories is $141.67. That is 21.63% above the last closing price of $116.48.
Analysts covering Mesa Laboratories currently have a consensus Earnings Per Share (EPS) forecast of $1.15 for the next financial year.
Find out moreWhat is the trend in the Mesa Laboratories share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mesa Laboratories. Over the past six months, its share price has outperformed the S&P500 Index by +8.61%.
As of the last closing price of $116.48, shares in Mesa Laboratories were trading -7% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Mesa Laboratories PE Ratio?
The Mesa Laboratories PE ratio based on its reported earnings over the past 12 months is 27.47. The shares last closed at $116.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Mesa Laboratories?
Mesa Laboratories' management team is headed by:
- John Sullivan - CHM
- Gary Owens - PRE
- John Sakys - CFO
- Brian Archbold - SVP
- Greg DiNoia - SVP
- Shannon Hall - DRC
- Jennifer Alltoft - IND
- Evan Guillemin - IND
- David Kelly - IND
- Shiraz Ladiwala - IND
- John Schmieder - IND